The US Department of Justice’s False Claims Act lawsuit against Teva over alleged illegal kickbacks involving Copaxone (glatiramer acetate) is “an overreach, based on a flawed legal theory,” the Israeli firm has argued in filing to have the case dismissed.
In August, the DoJ announced that it had filed an FCA complaint against Teva, alleging it violated the Anti-Kickback Statute by using two foundations as conduits for hundreds of millions in kickbacks to Medicare patients while raising the